Table 2.

Adverse events (safety population).

	Episodes, n (%) n = 28
Patients experiencing ≥1 adverse event, n (%)∗	21 (44.7)
Adverse event severity
Mild	23 (82.1)
Moderate	4 (14.3)
Severe	1 (3.6)
Adverse event
Headache	3 (10.7)
Allergic conjunctivitis	1 (3.6)
Allergic rhinitis	1 (3.6)
Ankle pain	1 (3.6)
Burning/eyelid swelling	1 (3.6)
Blurred vision	1 (3.6)
Conjunctival discomfort	1 (3.6)
Corneal superficial keratitis	1 (3.6)
Crusting of lashes	1 (3.6)
Dry eye	1 (3.6)
Eye pain	1 (3.6)
Lid erythema	1 (3.6)
Metallic taste	1 (3.6)
Ocular foreign body sensation	1 (3.6)
Pseudostenocardia†	1 (3.6)
Punctate keratopathy	1 (3.6)
Rhinitis sicca	1 (3.6)
Scheduled knee total endoprosthesis due to   gonarthrosis	1 (3.6)
Stomachache	1 (3.6)
Subjective poorer vision	1 (3.6)
Tinnitus	1 (3.6)
Tiredness and insomnia	1 (3.6)
Trace keratitis	1 (3.6)
Upper respiratory infection	1 (3.6)
Worsening of dorsal pain	1 (3.6)
Unknown‡	1 (3.6)

^∗Calculated as the percentage of patients in the safety population (n = 47).

^†Serious adverse event.

^‡A description was not available for 1 event in 1 patient.